

# NAFL Camden

14th June 2019

Dr Sarah Morgan, GP Hampstead Group Practice and Camden CCG Governing Body representative





# Primary /Secondary Care Interface



### Relationships

- 2013 a Hepatology working group was set up
- Camden and Islington with interested consultants, GPs and Public Health doctors and managerial support.
- Focussed on NAFLD and Hepatitis screening.
- Came to an end a few years later but the relationships persist which is the biggest enabler to progressing projects/pathways .....

# Making NAFLD a priority



- Competing priorities
- Clinical areas are often prioritised where financial savings can be realised especially short-term
- Need to persuade people that identifying NAFLD worthwhile and can improve outcomes

# **Abnormal LFT Pathway including NAFLD**



**Clinical Commissioning Group** 

- Created in 2013, revised 2016 and 2019
- Pathways only work if implemented and followed- our enablers included:-
  - ➤ An excellent established Camden GP website which includes a repository for 50 local pathways. Abnormal LFTs 2<sup>nd</sup> most popular pathway with >1500 hits/month
  - > A referral management centre that signposts clinicians to the pathway when relevant
- > The hepatology group GPs raising awareness through various borough wide communications
- Reinforced through various educational opportunities
- Royal Free London's evaluation of the pathway including uptake
- GP induction programme


# RFLH - Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver



Evaluation of 3012 patients across Camden and Islington

#### **Key findings**

- > 80% reduction in unnecessary referrals
- 5 fold increase in detection of advanced fibrosis
- > 3 fold increase in detection of cirrhosis
- Savings of £150k from referrals avoided



#### Abnormal Liver Function Tests Guidance Camden This guidance has been developed in collaboration with local specialists in Camden and Islington. Clinical Commissioning Group This is to assist GPs in decision making and is not intended to replace clinical judgment. Islinaton **READ Codes** Fatty Liver Suggested by J61y1- Non Alcoholic Fatty Liver Clinical Commissioning Group J610 - Alcoholic Fatty Liver Ultrasound and Liver Test Panel negative for other pathology Fatty Liver only on Ultrasound Fatty Liver on Ultrasound or Liver Use EMIS Fatty Liver Template with excess Alcohol Consumption **Test Panel Negative** >14U/Week without excess Alcohol Consumption Determine risk of advanced fibrosis by High Risk of Requesting ELF Test (FIB4 is Advanced Fibrosis > 10.5 'Determine risk of inaccurate with increased Refer Hepatology advanced fibrosis by alcohol consumption) Calculating FIB4 Separate gold top serum sample < 10.5 1.30 - 3.25< 1.30 > 3.25 Counsel to stop drinking + Consider referral to alcohol Services Low Risk High Risk Manage in primary care Request ELF Test of Advanced < 9.8 > 9.8 of Advanced **Fibrosis Fibrosis** Separate gold top serum sample Primary Care management of Fatty Liver NAFLD is part of metabolic syndrome and is a CVD risk Factor -Assess cardiovascular risk and treat Refer to Hepatology Cholesterol - QRISK & Consider Statin If no longer high risk, discharge to - For assessment of liver disease Can still initiate statin if ALT raised due to fatty liver primary care with Follow-up plan - For management of advanced fibrosis Diabetes Alcohol Hypertension - Screening and treatment of Portal ->10% Weight loss Hypertension - Annual LFTs, renal function, HABa1c, Lipids - HCC screening and management

#### References

Fibrosis stratification in NAFLD based upon:

yrs if LFTs still abnormal

FIB-4 McPherson S et al. Gut. 2010 Sep;59(9):1265-9. FIB4: (age [yr]x AST [U/L]) / ((PLT [109/L]) x (√ALT [U/L])) ELF: Enhanced Liver Fibrosis Test Rosenberg et al. Gastroenterology. 2004 Dec;127(6):1704-13.


Pathway Created Dec 2013 Reviewed Feb 2016 +2019 **Next Review Due** Feb 2022

NHS

Combining ELF and FIB4 in NAFLD Tanwar et al. HEPATOLOGY. 2012, 56, 264A.

- Reassess risk of advanced fibrosis (as above) in 1-3

Clinical contact for this pathway: Prof William Rosenberg william.rosenberg@nhs.net



Primary Care Management of elevated serum GGT. This guidance has been developed Camde in collaboration with local specialists in Camden and Islington. This is to assist GPs in Clinical Commissioning Grou decision making and is not intended to replace clinical judgment. Islingto **Isolated GGT Elevation** Clinical Commissioning Grou No significant alcohol Consumption Other abnormal LFTs Suspected NAFLD Alcohol-related >14U/Week Abnormal LFT Pathway Alcohol Pathway NAFLD Pathway Repeat GGT after I month still elevated Consider changing nonessential medication Review medications Perform abdominal US Referral if abnormal liver US Assess BMI cardiovascular risk scan Full blood count Q risk / lifestyle advice Treat metabolic abnormalities No cause identified Repeat in 6 months with other Other LFTs abnormal Abnormal LFTs Pathway LFTs panel including ALP Other LFTs normal

Perform: FBC, film, retics, haptoglobin,

Liver ultrasound (if not already done) And Refer Hepatology: Attach all results

LFTs, HbA1C, TFTs

Pathway Created Dec 2013 Reviewed Feb 2016+2019 **Next Review Due** Feb 2022

NH

## NAFL Camden



# Questions ????